A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

All eligible participants will be randomized to receive a single injection of either one of
the high-dose quadrivalent influenza vaccine formulations or one of the high-dose trivalent
influenza vaccines at Day 0. They will provide blood samples for hemagglutination inhibition
(HAI) testing. Safety information as solicited, unsolicited reactions, serious adverse
events, including adverse events of special interest will be collected in the trial.

Inclusion Criteria:

- Aged ≥ 65 years on the day of inclusion

- Informed consent form has been signed and dated

- Able to attend all scheduled visits and to comply with all trial procedures.

Exclusion Criteria:

- Participation at the time of trial enrollment (or in the 4 weeks preceding the trial
vaccination) or planned participation during the present trial period in another
clinical trial investigating a vaccine, drug, medical device, or medical procedure

- Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or
planned receipt of any vaccine prior to Visit 2

- Vaccination against influenza in the past 6 months

- Receipt of immune globulins, blood or blood-derived products in the past 3 months

- Known or suspected congenital or acquired immunodeficiency; or receipt of
immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
within the preceding 6 months; or long-term systemic corticosteroid therapy
(prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

- Known systemic hypersensitivity to any of the vaccine components, or history of a
life-threatening reaction to the vaccine used in the trial or to a vaccine containing
any of the same substances

- Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on
investigator's judgment

- Deprived of freedom by an administrative or court order, or in an emergency setting,
or hospitalized involuntarily

- Substance abuse that, in the opinion of the investigator, might interfere with the
trial conduct or completion

- Chronic illness that, in the opinion of the investigator, is at a stage where it might
interfere with trial conduct or completion

- Identified as an Investigator or employee of the Investigator or trial center with
direct involvement in the proposed trial, or identified as an immediate family member
(i.e., parent, spouse) of the Investigator or employee with direct involvement in the
proposed trial

- Personal or family history of Guillain-Barré syndrome

- Neoplastic disease or any hematologic malignancy (except localized skin or prostate
cancer that is stable at the time of vaccination in the absence of therapy and
subjects who have a history of neoplastic disease and have been disease free for ≥ 5
years)

- Known allergy to iodinated radiocontrast media

- Moderate or severe acute illness/infection (according to investigator judgment) on the
day of vaccination or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]). A
prospective subject should not be included in the trial until the condition has
resolved or the febrile event has subsided.